These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32523311)

  • 81. The increased IL-17-producing γδT cells promote tumor cell proliferation and migration in neuroblastoma.
    Zhang H; Chai W; Yang W; Han W; Mou W; Xi Y; Chen X; Wang H; Wang W; Qin H; Wang H; Ma X; Wang X; Gui J
    Clin Immunol; 2020 Feb; 211():108343. PubMed ID: 31931123
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Pallen MJ; Quraishi MN
    Dig Dis; 2017; 35(4):377-383. PubMed ID: 28468018
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
    Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
    Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Control of intestinal homeostasis through crosstalk between natural killer T cells and the intestinal microbiota.
    Dowds CM; Blumberg RS; Zeissig S
    Clin Immunol; 2015 Aug; 159(2):128-33. PubMed ID: 25988859
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life.
    Takiishi T; Fenero CIM; Câmara NOS
    Tissue Barriers; 2017 Oct; 5(4):e1373208. PubMed ID: 28956703
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inflammasome: A Double-Edged Sword in Liver Diseases.
    Luan J; Ju D
    Front Immunol; 2018; 9():2201. PubMed ID: 30319645
    [TBL] [Abstract][Full Text] [Related]  

  • 90. γδ T Cells Promote Steatohepatitis by Orchestrating Innate and Adaptive Immune Programming.
    Torres-Hernandez A; Wang W; Nikiforov Y; Tejada K; Torres L; Kalabin A; Adam S; Wu J; Lu L; Chen R; Lemmer A; Camargo J; Hundeyin M; Diskin B; Aykut B; Kurz E; Kochen Rossi JA; Khan M; Liria M; Sanchez G; Wu N; Su W; Adams S; Haq MIU; Farooq MS; Vasudevaraja V; Leinwand J; Miller G
    Hepatology; 2020 Feb; 71(2):477-494. PubMed ID: 31529720
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
    Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
    Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gut-liver immunity.
    Trivedi PJ; Adams DH
    J Hepatol; 2016 May; 64(5):1187-1189. PubMed ID: 26686270
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy.
    Song Y; Liu Y; Teo HY; Liu H
    Front Immunol; 2022; 13():914839. PubMed ID: 35747139
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Influence of Leptin and Adiponectin Supplementation on Intraepithelial Lymphocyte and Microbiota Composition in Suckling Rats.
    Grases-Pintó B; Abril-Gil M; Castell M; Rodríguez-Lagunas MJ; Burleigh S; Fåk Hållenius F; Prykhodko O; Pérez-Cano FJ; Franch À
    Front Immunol; 2019; 10():2369. PubMed ID: 31708912
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The enteric microbiome in hepatobiliary health and disease.
    Tabibian JH; Varghese C; LaRusso NF; O'Hara SP
    Liver Int; 2016 Apr; 36(4):480-7. PubMed ID: 26561779
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Neutrophils in liver diseases: pathogenesis and therapeutic targets.
    Liu K; Wang FS; Xu R
    Cell Mol Immunol; 2021 Jan; 18(1):38-44. PubMed ID: 33159158
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Role of B Cells in Adult and Paediatric Liver Injury.
    Patel AM; Liu YS; Davies SP; Brown RM; Kelly DA; Scheel-Toellner D; Reynolds GM; Stamataki Z
    Front Immunol; 2021; 12():729143. PubMed ID: 34630404
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Microbiota, immunity and the liver.
    Vaikunthanathan T; Safinia N; Lombardi G; Lechler RI
    Immunol Lett; 2016 Mar; 171():36-49. PubMed ID: 26835593
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Fibrosis and the intestinal microbiome; a focus on chronic liver disease.
    Beraza N
    Curr Opin Pharmacol; 2019 Dec; 49():76-81. PubMed ID: 31670055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.